Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 89, Issue 3, 2014, Pages 509-517

  Kim, D W Nathan ^a   Cho, L Chinsoo ^d   Straka, Christopher ^a   Christie, Alana ^c   Lotan, Yair ^b   Pistenmaa, David ^a   Kavanagh, Brian D ^e   Nanda, Akash ^f   Kueplian, Patrick ^g   Brindle, Jeffrey ^h   Cooley, Susan ^a   Perkins, Alida ^a   Raben, David ^e   Xie, Xian Jin ^c   Timmerman, Robert D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF FLORIDA HEALTH   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Prairie Lakes Healthcare System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; PATIENT MONITORING; RADIOTHERAPY;

CLINICAL STUDY; LOCALIZED PROSTATE CANCER; METHODS AND MATERIALS; PROSTATE CANCERS; RECTAL TOXICITY; STEREOTACTIC BODY RADIATION THERAPY; THRESHOLD DOSE; TREATMENT PLANNING;

TOXICITY;

ADULT; AGED; ARTICLE; COLOSTOMY; DOSIMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE ESCALATION; RECTUM DISEASE; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT PLANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM GRADING; ORGANS AT RISK; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIATION TOLERANCE; RADIOSURGERY; RADIOTHERAPY DOSAGE; RECTUM; TUMOR BURDEN;

EID: 84902073583     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.03.012     Document Type: Article

References (29)

1. B.L. Madsen, R.A. Hsi, and H.T. Pham et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results Int J Radiat Oncol Biol Phys 67 2007 1099 1105
2. D.B. Fuller, J. Naitoh, and C. Lee et al. Virtual HDR Cyberknife treatment for localized prostatic carcinoma: Dosimetry comparison with hdr brachytherapy and preliminary clinical observations Int J Radiat Oncol Biol Phys 70 2008 1588 1597
3. C.R. King, J.D. Brooks, and H. Gill et al. Stereotactic body radiotherapy for localized prostate cancer: Interim results of a prospective phase II clinical trial Int J Radiat Oncol Biol Phys 73 2009 1043 1048
4. A.J. Katz, M. Santoro, and R. Ashley et al. Stereotactic body radiotherapy for organ-confined prostate cancer BMC Urol 10 2010 1
5. D.E. Freeman, and C.R. King Stereotactic body radiotherapy for low-risk prostate cancer: Five-year outcomes Radiat Oncol 6 2011 3
6. C.R. King, J.D. Brooks, and H. Gill et al. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer Int J Radiat Oncol Biol Phys 82 2012 877 882
7. T.P. Boike, Y. Lotan, and L.C. Cho et al. Phase i dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer J Clin Oncol 29 2011 2020 2026
8. W.B. Cai, S.A. Roberts, and E. Bowley et al. Differential survival of murine small and large intestinal crypts following ionizing radiation Int J Radiat Biol 71 1997 145 155
9. C.S. Potten Radiation, the ideal cytotoxic agent for studying the cell biology of tissues such as the small intestine Radiat Res 161 2004 123 136
10. C. Park, L. Papiez, and S. Zhang et al. Universal survival curve and single fraction equivalent dose: Useful tools in understanding potency of ablative radiotherapy Int J Radiat Oncol Biol Phys 70 2008 847 852
11. M.W. Skwarchuk, A. Jackson, and M.J. Zelefsky et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): Multivariate analysis and dose-response Int J Radiat Oncol Biol Phys 47 2000 103 113
12. D.M. Herold, A.L. Hanlon, and G.E. Hanks Diabetes mellitus: A predictor for late radiation morbidity Int J Radiat Oncol Biol Phys 43 1999 475 479
13. G.C. Barnett, G. De Meerleer, and S.L. Gulliford et al. The impact of clinical factors on the development of late radiation toxicity: Results from the Medical Research Council RT01 trial (ISRCTN47772397) Clin Oncol (R Coll Radiol) 23 2011 613 624
14. P.J. Eifel, A. Jhingran, and D.C. Bodurka et al. Correlation of smoking history and other patient characteristics with major complications of pelvic radiation therapy for cervical cancer J Clin Oncol 20 2002 3651 3657
15. G.P. Swanson, and S. Stathakis Rectal dose constraints for intensity modulated radiation therapy of the prostate Am J Clin Oncol 34 2011 188 195
16. F.M. Waterman, and A.P. Dicker Probability of late rectal morbidity in 125I prostate brachytherapy Int J Radiat Oncol Biol Phys 55 2003 342 353
17. K.M. Snyder, R.G. Stock, and S.M. Hong et al. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis Int J Radiat Oncol Biol Phys 50 2001 335 341
18. G.S. Merrick, W.M. Butler, and A.T. Dorsey et al. Rectal dosimetric analysis following prostate brachytherapy Int J Radiat Oncol Biol Phys 43 1999 1021 1027
19. K. Wallner, J. Roy, and L. Harrison Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy Int J Radiat Oncol Biol Phys 32 1995 465 471
20. M. Ghilezan, A. Martinez, and G. Gustason et al. High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: Preliminary toxicity data Int J Radiat Oncol Biol Phys 83 2012 927 932
21. A. Pollack, G.K. Zagars, and G. Starkschall et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial Int J Radiat Oncol Biol Phys 53 2002 1097 1105
22. D.S. Followill, D. Kester, and E.L. Travis Histological changes in mouse colon after single- and split-dose irradiation Radiat Res 136 1993 280 288
23. J. Papillon Intracavitary irradiation of early rectal cancer for cure. A series of 186 cases. 1975 Dis Colon Rectum 37 1994 88 94
24. F. Paris, Z. Fuks, and A. Kang et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice Science 293 2001 293 297
25. K. Konishi, Y. Yoshioka, and F. Isohashi et al. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer Int J Radiat Oncol Biol Phys 75 2009 1003 1007
26. D.C. Weber, T. Zilli, and J.P. Vallee et al. Intensity modulated proton and photon therapy for early prostate cancer with or without transperineal injection of a polyethylen glycol spacer: A treatment planning comparison study Int J Radiat Oncol Biol Phys 84 2012 e311 e318
27. M. Pinkawa, N.E. Corral, and M. Caffaro et al. Application of a spacer gel to optimize three-dimensional conformal and intensity modulated radiotherapy for prostate cancer Radiother Oncol 100 2011 436 441
28. G. Hatiboglu, M. Pinkawa, and J.P. Vallee et al. Application technique: Placement of a prostate-rectum spacer in men undergoing prostate radiation therapy BJU Int 110 2012 E647 E652
29. R.C. Susil, T.R. McNutt, and T.L. DeWeese et al. Effects of prostate-rectum separation on rectal dose from external beam radiotherapy Int J Radiat Oncol Biol Phys 76 2010 1251 1258